
|Articles|September 23, 2015
Shaji Kumar on Later Lines of Treatment for Myeloma
Author(s)Shaji Kumar
There are several agents available for patients who experience recurrence, Kumar says, though nearly all of them have the potential to move to an earlier setting.
Advertisement
Shaji Kumar, professor of medicine, Division of Hematology, Mayo Clinic, provides an overview of later lines of therapy for patients with multiple myeloma.
There are several agents available for patients who experience recurrence, Kumar says, though nearly all of them have the potential to move to an earlier setting.
Advertisement
Advertisement
Advertisement
Trending on CURE
1
FDA Updates Safety Warnings for Common Chemotherapy Drugs
2
KTX-1001 Elicits Responses in Some With Multiple Myeloma
3
FDA Removes Use Limitation for Yescarta in Primary CNS Lymphoma
4
New Combination Treatment Approach Studied in Pancreatic Cancer
5




